DESTINY-Breast03 Phase 3 Study Results
Background
10
Daiichi-Sankyo
DESTINY-Breast03
Progression-Free Survival Probability, %
100
PFS by BICR¹‚ª
mPFS (95% CI), mo
12-mo PFS rate
(95% CI), %
T-DXd
NR (18.5-NE)
75.8
(69.8-80.7)
HR (95% CI)
80
60
40
2
+
Censor
T-DXd (n = 261)
0
T-DM1 (n = 263)
0 1
2 3 4 5 6 7 8
Patients Still at Risk:
T-DM1
6.8 (5.6-8.2)
34.1
(27.7-40.5)
0.28 (0.22-0.37)
P= 7.8 X 10-22
HHHHH
9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32
Time, months
T-DXD (261) 261 256 250 244 240 224 214 202 200 183 168 164 150 132 112 105 79 84 53 45 38 29 25 19
T-DM1 (263) 263 252 200 163 155 132 108 98 93 78 65 60 51 43 37 34 29 23 21 16 12 8 8 4 1 1 1
10 8 5
3
2
0
1
1
1 1 1 0
T-DXd, a HER2-targeted ADC, was approved for
the treatment of patients with HER2+
unresectable or mBC who have received a prior
anti-HER2 therapy in the metastatic or
neoadjuvant/adjuvant setting and had recurrence
during or within 6 months after therapy²
DESTINY-Breast03 (NCT03529110) investigated
T-DXd vs T-DM1 in patients with HER2+
unresectable or mBC
■ In the primary analysis (May 21, 2021),
T-DXd was superior to T-DM1 for PFS by
BICR (primary endpoint)1
■ Overall health status and QoL was
maintained with T-DXd and numerically
favored T-DXd over T-DM13
ADC, antibody-drug conjugate; BICR, blinded independent central review; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; mBC, metastatic breast cancer; mPFS, median progression-free survival; PFS, progression-free survival; QoL, quality
of life; T-DM1, trastuzumab emtansine; T-DXd, trastuzumab deruxtecan. 1. Cortés J et al. N Engl J Med. 2022;386:1143-1154. 2. Enhertu (fam-trastuzumab deruxtecan-nxki) for injection, for intravenous use. Daiichi Sankyo, Inc; 2022. 3. Curigliano G et al.
Presented at ESMO Breast Cancer meeting; May 3-5, 2022; Berlin, Germany. Presentation 1630. From New England Journal of Medicine, Cortés J et al, Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer, Vol. 386, Pages 1143-1154.
Copyright ©2022 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
ASCO 2022 #1000 Oral
24
24View entire presentation